SOURCE: Galea Life Sciences, Inc.

Galea Life Sciences, Inc.

April 15, 2009 10:27 ET

Galea's Nutraplete ™ Approved for Medicaid Reimbursement in Key Market States, Further Approvals Sought

AVENTURA, FL--(Marketwire - April 15, 2009) - Galea Life Sciences, Inc., maker of Nutraplete™ therapeutic drink mix and a pioneer in the field of therapeutic nutrition, announced that it its proprietary Nutraplete Therapeutic Drink Mix, the first dietary supplement product created specifically for people living with HIV/AIDS, has been approved for Medicaid Reimbursement in New York, New Jersey, Connecticut, Nevada, Illinois and Washington State, which together account for nearly 500,000 persons living with HIV/AIDS.

The next group of states in which the Company has applied for Medicaid reimbursement approval are California, Texas, Florida, Pennsylvania, Maryland and Washington, D.C. Once these additional Medicaid jurisdictions become Nutraplete-ready, the Company will be able to market, with partner Allion Healthcare, Inc. (NASDAQ: ALLI), to approximately 910,000 potential Nutraplete consumers, or approximately 70 % of people living with HIV/AIDS in the U.S. In addition, there are 15 states where Nutraplete can immediately be prescribed and reimbursed by Medicaid with prior approval.

"Our strategy is to make Nutraplete available through Medicaid pharmacy programs in areas of this country where it is most needed, and as soon as possible," said Paul Zuromski, Chairman & President of Galea Life Science, Inc. "This effort is being facilitated with our exclusive distributor, Allion Healthcare's MOMS Pharmacy, helping to make Nutraplete available to people living with HIV/AIDS in these Medicaid-approved states."

About Nutraplete™ and Marketing Partner MOMS Pharmacy

Nutraplete Therapeutic Drink Mix is the first therapeutic nutritional dietary supplement created specifically to help people living with HIV/AIDS. This multi-nutritional, therapeutic "functional food" includes pharmaceutical grade supplements that may provide health benefits by addressing common nutritional deficiencies. Nutraplete is available by prescription and approved by many state Medicaid pharmacy programs. For more information:

Nutraplete is distributed exclusively in the U.S. by Allion Healthcare, Inc. (NASDAQ: ALLI) under its MOMS Pharmacy trade name. MOMS Pharmacy is a specialty pharmacy that is focused exclusively on providing medications and support services to people living with HIV/AIDS. Visit

About Galea Life Sciences, Inc.

Galea Life Sciences, Inc. is a company devoted to discovering, developing and delivering specialized therapeutic functional food products and dietary supplements that complement prescribed drug therapy regimens and help patients successfully tolerate and gain maximum benefit from them.

Our vision is to become a worldwide leader in delivering new ways to assist health care professionals and their patients, assuring that patients are able to tolerate and maintain their therapeutic regimens and help improve the quality of their lives. We don't make the medicines. We make products that help the medicines work better.

Certain statements in this release constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast," "project," "intend," "expect," "should," "would," and similar expressions and all statements, which are not historical facts, are intended to identify forward-looking statements. These forward-looking statements involve and are subject to known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance (finance or operating) or achievements to differ from future results, performance (financing and operating) or achievements expressed or implied by such forward-looking statements. Statements herein express management's beliefs and expectations regarding future performance and are forward-looking and involve risks and uncertainties, including, but not limited to, the ability to negotiate outstanding prior debts of acquired companies; properly identify acquisition partners; adequately perform due diligence; manage and integrate acquired businesses; react to quarterly fluctuations in results; raise working capital and secure other financing; respond to competition and rapidly changing technology; deal with market and stock price fluctuations; and other risks.

Contact Information

  • Contact:
    Galea Life Sciences Inc.
    Paul Zuromski